Christopher G. Williams

Christopher G. Williams

Auto-generated profile, based on publicly available information

Christopher G. Williams

Department of Chemistry, University of California, Riverside, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2025 in Science Advances
Verified
Journal Article
Open access
SWSonglin Wang
Songlin Wang
TRThirupathi Ravula
Thirupathi Ravula
JSJohn A. Stringer
John A. Stringer
PGPeter L. Gor’kOv
Peter L. Gor’kOv
OWOwen A. Warmuth
Owen A. Warmuth
CRChad M. Rienstra
Chad M. Rienstra
Nuclear magnetic resonance (NMR) spectroscopy is a powerful technique with broad impact across the physical and life sciences, and ultrahigh field (UHF), gigahertz-class NMR spectrometers offer exceptional performance, including superior resolution and sensitivity. In solid-state NMR (SSNMR), resolution is primarily constrained by instrumentation rather than molecular tumbling, making it well suited for studying large and complex systems. To fully leverage UHF magnets for SSNMR, it is essential to eliminate line broadening arising from magnetic field drift and couplings among the nuclear spins. We address these challenges using external 2 H lock to compensate for the field drift and long-observation-window band-selective homonuclear decoupling to suppress 13 C homonuclear couplings. We achieve better than 0.2–parts per million resolution in proteins up to 144 kilodalton, enabling unique site resolution for more than 500 amide backbone pairs in two-dimensional experiments. This exceeds the resolution available from solution NMR for large biological molecules, greatly expanding the potential of gigahertz-class NMR for research in life sciences.

22 December 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RPRavi Shankar Palani
Ravi Shankar Palani
CWChristopher G. Williams
Christopher G. Williams
DTDev Thacker
Dev Thacker
RSRobert Silvers
Robert Silvers
FQFang Qian
Fang Qian
RGRobert G. Griffin
Robert G. Griffin
Aducanumab, a human IgG1 antibody with plaque-clearing effects and modest clinical benefit, binds selectively to aggregated Aβ via the N-terminal region. Yet, the molecular details of how the antibody engages Aβ 1-42 fibrils remain unresolved. Using magic-angle spinning NMR, we show that binding of aducanumab preserves the overall architecture of the Aβ 1-42 fibril core while inducing significant structural and dynamic perturbations in the N-terminal region. Antibody binding markedly reduces flexibility in this domain, with the appearance of side-chain resonances from residues D1, E3, and histidine (likely H6) in dipolar-based experiments. These side chains—previously observed in scalar-coupling spectra of the unbound state—indicate rigidification of residues that were dynamic. The interaction extends to S8 and Y10, indicating broader fibril engagement than the minimal epitope (residues 3 to 7) defined in fragment-based studies. Perturbations in the C-terminal segment (G37–A42) are consistent with its spatial proximity to the antibody-bound N termini of neighboring monomers. Cryo-TEM images reveal fibrils bundling in the presence of aducanumab, consistent with lateral association via antibody cross-linking, supporting a model where surface coating and steric hindrance suppress secondary nucleation. This mode of action restricts monomer access to catalytic sites on the fibril surface, resulting in partial inhibition (~threefold reduction) of secondary nucleation. The effect depends on high avidity and relatively high stoichiometry but is ultimately limited by antibody size relative to N-terminal spacing along the fibril. These findings provide atomic-level insights into aducanumab’s binding mode and supply a structural framework for understanding antibody-mediated fibril recognition and for guiding next-generation therapies targeting Aβ aggregates in Alzheimer’s disease.

27 July 2025 in Biomolecular NMR Assignments
Verified
Journal Article
Closed access
PDF file
CWChristopher G. Williams
Christopher G. Williams
SWSonglin Wang
Songlin Wang
ATAlexander F. Thome
Alexander F. Thome
OWOwen A. Warmuth
Owen A. Warmuth
VSVarun Sakhrani
Varun Sakhrani
LMLeonard J. Mueller
Leonard J. Mueller

3 November 2025 in bioRxiv
Verified
Preprint
Open access
RPRavi Shankar Palani
Ravi Shankar Palani
CWChristopher G. Williams
Christopher G. Williams
DTDev Thacker
Dev Thacker
RSRobert Silvers
Robert Silvers
FQFang Qian
Fang Qian
RGRobert G. Griffin
Robert G. Griffin
Aducanumab, a human IgG1 antibody with plaque-clearing effects and modest clinical benefit, binds selectively to aggregated Aβ via the N-terminal region. Yet, the molecular details of how the antibody engages Aβ 1-42 fibrils remain unresolved. Using magic-angle spinning nuclear magnetic resonance, we show that binding of aducanumab preserves the overall architecture of the Aβ 1-42 fibril core while inducing significant structural and dynamic perturbations in the N-terminal region. Antibody binding markedly reduces flexibility in this domain, with the appearance of sidechain resonances from residues D1, E3, and histidine (likely H6) in dipolar-based experiments. These sidechains—previously observed only in scalar-coupling spectra of the unbound state—indicate rigidification of residues that were dynamic. The interaction extends to S8 and Y10, indicating broader fibril engagement than the minimal epitope (residues 3–7) defined in fragment-based studies. Perturbations in the C-terminal segment (G37–A42) are consistent with its spatial proximity to the antibody-bound N-termini of neighboring monomers. Cryo-TEM images reveal fibrils bundling in the presence of aducanumab, consistent with lateral association via antibody cross-linking, supporting a model where surface coating and steric hindrance suppress secondary nucleation. This mode of action restricts monomer access to catalytic sites on fibril surface, resulting in partial inhibition (∼three-fold reduction) of secondary nucleation. The effect depends on high avidity and relatively high stoichiometry, but is ultimately limited by antibody size relative to N-terminal spacing along the fibril. These findings provide atomic-level insights into aducanumab’s binding mode and supply a structural framework for understanding antibody-mediated fibril recognition and for guiding next-generation therapies targeting Aβ aggregates in Alzheimer’s disease. Significance Statement: Understanding how therapeutic antibodies interact with amyloid-β (Aβ) fibrils is crucial for developing effective Alzheimer’s disease treatments. Magic angle spinning NMR provides atomic-level insights into the binding of aducanumab to mature Aβ 1-42 fibrils. Aducanumab binding preserves the fibril’s core structure but slows the dynamics of the N-terminal domain of Aβ. This interaction, which spans D1 to S8 and extends to Y10 on the fibril surface, is consistent with a mechanism in which N-terminal binding by the antibody interferes with aggregation steps like secondary nucleation. These findings detail how aducanumab engages its target fibril and provides insights relevant to other clinically approved antibodies and next-generation therapies that recognize the Aβ N-terminal region.

19 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CWChristopher G. Williams
Christopher G. Williams
SWSonglin Wang
Songlin Wang
ATAlexander F. Thome
Alexander F. Thome
OWOwen A. Warmuth
Owen A. Warmuth
VSVarun Sakhrani
Varun Sakhrani
LMLeonard J. Mueller
Leonard J. Mueller
13 C and 15 N backbone chemical shift assignments are reported for the 28.5 kDa protein Toho-1 β-lactamase, a Class A extended spectrum β-lactamase. A very high level of assignment completeness (97% of the backbone) is enabled by the combined sensitivity and resolution gains of ultrahigh-field NMR spectroscopy (1.1 GHz), improved probe technology, and optimized pulse sequences. The assigned chemical shifts agree well with our previous solution-state NMR assignments, indicating that the secondary structure is conserved in the solid state. These assignments provide a foundation for future investigations of sidechain chemical shifts and catalytic mechanism.

15 September 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CWChristopher G. Williams
Christopher G. Williams
SWSonglin Wang
Songlin Wang
VCVeronica Carta
Veronica Carta
PLPatricia S. Langan
Patricia S. Langan
ATAlexander F. Thome
Alexander F. Thome
LMLeonard J. Mueller
Leonard J. Mueller
The determination of active-site protonation states is critical for a full mechanistic understanding of enzyme catalysis and inhibition. Here, we employ NMR crystallography—the integrated combination of solid-state NMR spectroscopy, X-ray diffraction, and first-principles computational chemistry—to determine the protonation states of the active site of Toho-1 β-lactamase in complex with the non-β-lactam inhibitor avibactam. We report two X-ray crystal structures of the Toho-1:avibactam complex, along with high-field solid-state NMR measurements that enable near-complete backbone and side-chain resonance assignments. To overcome the computational scaling limits that have traditionally hindered NMR crystallography in large systems, we use an accelerated workflow in which machine-learning interatomic potentials enable efficient geometry refinement prior to density functional theory chemical shift calculations. For Toho-1, quantitative analysis of the active-site chemical shifts and chemical shift tensors using this hybrid protocol reveals that the key active-site side chains retain their canonical charge states in the presence of avibactam, with Lys73 and Lys234 protonated and positively charged, and Glu166 deprotonated and poised to function as a general base. Contrary to recent proposals suggesting that avibactam inhibits by suppressing essential proton transfers through p K a perturbations, our data point to a more direct chemical origin arising from the intrinsic resistance of the Ser70-avibactam carbamoyl linkage to hydrolysis.